血管内治疗后颅内出血:联合或不联合静脉阿替普酶的患者水平荟萃分析
该个体参与者数据荟萃分析纳入6项随机临床试验的2313例前循环大血管闭塞性卒中患者,比较静脉溶栓联合血管内治疗与单纯血管内治疗。无症状和有症状颅内出血均与更差功能结局相关。
要点
- 静脉溶栓联合血管内治疗较单纯血管内治疗轻度增加任何颅内出血和脑实质血肿风险。
- 无症状颅内出血和有症状颅内出血均与更差功能结局独立相关。
- 颅内出血影像学模式与患者结局呈分级关联。
核心结论
- 与单纯血管内治疗相比,静脉阿替普酶联合血管内治疗轻度增加颅内出血风险,尤其是任何脑实质血肿。
- 颅内出血与更差功能结局相关,但该效应可能被静脉溶栓在最终成功再灌注和早期再灌注中的获益所抵消。
研究设计与样本
- 研究为个体参与者数据荟萃分析,纳入比较单纯血管内治疗与静脉溶栓联合血管内治疗前循环大血管闭塞性卒中的随机临床试验。
- 共纳入6项研究、2313例参与者,其中静脉溶栓联合血管内治疗组1160例,单纯血管内治疗组1153例;中位年龄71岁(IQR 62-78),女性1025例(44%)。
- 检索PubMed和MEDLINE从建库至2023年3月9日,采用随机效应模型合并数据,数据分析时间为2024年4月至2025年2月。
主要发现
- 任何颅内出血发生于2261例参与者中的768例(34%)。
- 与无颅内出血者相比,无症状颅内出血(调整共同OR 0.55;95%CI 0.46-0.65)和有症状颅内出血(调整共同OR 0.08;95%CI 0.05-0.13)均与更差功能结局相关。
- 颅内出血影像学模式与患者结局存在分级关联。
关键数值与推荐
- 颅内出血及其亚型依据海德堡出血分类定义,包括出血性梗死1型(HI1)、出血性梗死2型(HI2)、脑实质血肿1型(PH1)、脑实质血肿2型(PH2)及其他,并区分症状性与无症状性颅内出血。
临床怎么用
- 对于前循环大血管闭塞且直接就诊于具备血管内治疗能力中心的急性缺血性卒中患者,静脉溶栓联合血管内治疗虽轻度增加颅内出血风险,但需权衡其在再灌注方面的潜在获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: For patients with acute ischemic stroke due to anterior circulation large vessel occlusion and presenting directly to endovascular treatment (EVT)-capable centers, intravenous thrombolysis (IVT) before EVT raises concerns about intracranial hemorrhage (ICH), but details are not well understood. OBJECTIVE: To determine the frequency and subtypes of ICH in patients treated with IVT plus EVT vs EVT alone and to determine the association between various ICH subtypes and patient functional outcomes. DATA SOURCES: PubMed and MEDLINE were searched from database inception through March 9, 2023. STUDY SELECTION: Randomized clinical trials comparing EVT alone with IVT plus EVT for anterior circulation large vessel occlusion stroke were included. DATA EXTRACTION AND SYNTHESIS: Individual participant data were extracted following the Preferred Reporting Items for Systematic Review and Meta-Analyses of independent participant data (PRISMA-IPD) reporting guidelines. Data were pooled using a random-effects model. Data were analyzed between April 2024 and February 2025. MAIN OUTCOMES AND MEASURES: The primary outcomes were ICH and its subtypes according to the Heidelberg Bleeding Classification (hemorrhagic infarction type 1 [HI1], hemorrhagic infarction type 2 [HI2], parenchymal hematoma type 1 [PH1], parenchymal hematoma type 2 [PH2], and others; symptomatic or asymptomatic ICH), which were evaluated using a mixed-model approach with multinomial or binary regression. RESULTS: The analysis involved 2313 participants (1160 allocated to the IVT plus EVT group vs 1153 to EVT alone; median [IQR] age, 71 [62-78] years; 1025 female participants [44%]) from 6 studies. Any ICH occurred in 768 of 2261 participants (34%). IVT was associated with an increased rate of any ICH (411 of 1133 [36%] vs 357 of 1128 [32%]; adjusted odds ratio [OR], 1.23; 95% CI, 1.02-1.49; P = .03) and a higher rate of any parenchymal hematoma (PH1 or PH2) (82 of 1133 [7%] vs 61 of 1128 [5%]; adjusted OR, 1.54; 95% CI, 1.02-2.34; P = .04). Compared with participants without ICH, asymptomatic ICH (adjusted common OR, 0.55; 95% CI, 0.46-0.65) and symptomatic ICH (adjusted common OR, 0.08; 95% CI, 0.05-0.13) were both associated with worse functional outcomes, and there was a graded association of ICH radiologic patterns and patient outcomes. CONCLUSIONS AND RELEVANCE: In this individual participant data meta-analysis, compared with EVT alone, IVT plus EVT modestly increased the risk of ICH, notably any parenchymal hematoma. Although ICH was associated with worse functional outcomes, this effect may be offset by IVT's benefit in final successful reperfusion and early reperfusion.
引用
- Zhou Y, Zhang L, Cavalcante F, et al. Intracranial Hemorrhage in Patients With Stroke After Endovascular Treatment With or Without IV Alteplase: An Individual Participant Data Meta-Analysis. JAMA Neurol. 2025. PMID: 40788598. doi:10.1001/jamaneurol.2025.2610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。